Vor Bio raises $150M in private placement; appoints two new directors

Vor Biopharma Inc.

Private placement of 13.9M shares at $10.81 for gross proceeds of ~$150M.
New/existing investors include RA Capital, Forbion, Frazier Life Sciences, Caligan, Logos, Venrock.
Proceeds to advance telitacicept Phase 3 trials for myasthenia gravis and Sjögren's disease.
Director Sarah Reed resigned; Andrew Levin (RA Capital) and Wouter Joustra (Forbion) appointed.
Levin and Joustra receive standard director fees and option grants of 3,000 shares each.

item 1.01item 3.02item 5.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.